Introduction
============

Hypertrophic cardiomyopathy (HCM) is a genetic myocardial disorder characterized by ventricular hypertrophy (VH), which is frequently asymmetrical in the interventricular septum and can lead to a dynamic obstruction of the left ventricle (LV) outflow tract.^[@r1]^ It is the main cause of sudden cardiac death (SCD) in young people, with a 2-4% annual mortality rate in adults and 6% in adolescents and children.^[@r2]^ A benign outcome of HCM may also occur, such as late onset, mild hypertrophy, and a history of non-malignant events.^[@r3]^ Modifier genes, environmental influences, genetic variant diversity and the effect of multiple variants could explain the great clinical heterogeneity between individuals of the same family or from different families.^[@r4]^

HCM is a relatively common (0.2%) Mendelian disorder, caused mainly by mutations in sarcomere protein genes, most commonly those encoding β-myosin heavy chain (*MYH7*), myosin-binding protein C (*MYBPC3*) and troponin T (*TNNT2*).^[@r5]^ Recent studies suggest that this prevalence is even higher, around 1:200, in the general population,^[@r6]^ and around 5% of those who have HCM carry more than one disease-causing gene variant.^[@r7]-[@r9]^ The hypothesis of gene dosage effects in patients with multiple variants is supported by some authors who have reported a more severe clinical feature, with greater risk of SCD, major LV hypertrophy, and earlier onset of HCM.^[@r7],[@r10]^

In this context, we present a case herein in which a compound heterozygous variant led to a HCM manifestation with disease phenotype magnification.

Methods
=======

Subjects
--------

The proband with clinical HCM diagnosis was referred to genetic analysis at the National Cardiology Institute (Instituto Nacional de Cardiologia - INC) in Rio de Janeiro. A genealogical tree, including the highest possible number of generations, was built based on his family history. Family members were submitted to clinical assessments and genetic investigations. The local ethics committee approved this study. Written informed consent was obtained for every analyzed family member.

Clinical assessment
-------------------

The proband underwent clinical and cardiovascular examination, including a 12-lead electrocardiogram (ECG), transthoracic echocardiography (TTE) and 24-hour Holter monitoring. Diagnosis of HCM was based on TTE: major echo diagnostic criteria were defined by a maximal LV end-diastolic wall thickness ≥ 15 mm. The same clinical examination was performed for the phenotypic analyses of all family members, and cardiac magnetic resonance imaging (CMR) was requested as a complementary exam.

A risk score proposed by the European Cardiac Society (ESC) was used to predict the risk for SCD in five years for patients with HCM.^[@r11]^

Genetic analysis
----------------

### Sanger sequencing

The genetic analysis of the proband was performed through direct sequencing of the three sarcomere genes: *MYH7*, *MYBPC3* and *TNNT2*. Genomic DNA obtained from leukocytes according to Miller et al.^[@r12]^ was submitted to a polymerase chain reaction (PCR) of all coding exons, using previously described primers and others designed by us ([Tables 1](#t1){ref-type="table"}, [2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}), and the same amplification program. PCR products were cleaned-up with EXOSAP-IT (Affymetrix, Santa Clara, CA), subjected to the sequencing reaction using the BigDye^®^ Terminator v3.1 reagent (Thermo Fisher Scientific, Waltham, MA) and subsequently analyzed on a ABI 3500xL genetic analyzer (Thermo Fisher Scientific, Waltham, MA). Sequence analyses were performed using the Geneious^®^ v.6.1.6 software package (Biomatters, Auckland, NZ). The family was submitted to a mutation-specific screening according to the HRS/EHRA expert consensus statement.^[@r13]^

###### 

Primers for MYH7 sequencing

  Exon                                  Forward Primer 5\'-3\'       Reverse Primer 5\'-3\'      Amplicon^[†](#TFN2){ref-type="table-fn"}^   A.T.^[‡](#TFN3){ref-type="table-fn"}^
  ------------------------------------- ---------------------------- --------------------------- ------------------------------------------- ---------------------------------------
  3                                     TCTTGACTCTTGAGCATGGTGCTA     TCTGTCCACCCAGGTGTACAGGTG    381 bp                                      62ºC
  4                                     AGGAAGGAGGGAAAGCCCAGGCTG     TCTGCATGCACTCAATCTGAGTAA    380 bp                                      62ºC
  5                                     ATCTTTCTCTAACTCCCAAAATCA     ACTCACGTGATCAGGATGGACTGG    398 bp                                      60ºC
  6                                     TGTCACCGTCAACCCTTACAAGTG     GAGGCTGAGTCTATGCCTCGGGG     394 bp                                      62ºC
  7                                     CTTGCTGGTCTCCAGTAGTATTGT     CTGCGGTACAGGACCTTGGAGGGC    198 bp                                      62ºC
  8                                     GCCCTCCAAGGTCCTGTACCGCAG     GTCCAAGTCCCAAGGCCAAGGTCA    200 bp                                      62ºC
  9                                     GACAACTCCTCCCGCTTCGTG        AACAGAGGGAGGGAGGGGAGAG      281 bp                                      62ºC
  10                                    CCTTTTGCTTGCTACATTTATCAT     GCCACAAGCAGAGGGGACCAG       252 bp                                      60ºC
  11                                    CTGCTTCCTCAGGCCATGTGCTGT     ACCAATGGCCAGAGTCTTAGCTCT    284 bp                                      62ºC
  12                                    CACAGGGATTAAGGAGACAAGTTT     TTACAGCTGCCCCAAGAATC        273 bp                                      58ºC
  13                                    AGTCATCTCTTTACCAACTTTGCTA    ATTATCATCTGAAGATGGACCCACC   186 bp                                      62ºC
  14                                    CAAGTTCACTCTTCCCAACAACCCT    ATGTGGGAGCGAGTGAGTGATTGTT   258 bp                                      62ºC
  15                                    ACTCACACCCACTTTCTGACTGCTC    GAATTCAGGTGGTAAGGCCAAAGAG   247 bp                                      62ºC
  16                                    ATAACTGTACTCAGAGCTGAGCCTA    TCCATCCCACTGAGTCTGTAAACCT   578 bp                                      62ºC
  17                                    GCAAATGCCAGCAAGGATGTAAAG     AGAGAAGGGAGATGGGAAGTAA      359 bp                                      58ºC
  18                                    CATCTCTGTGACTTCTCGAATTCT     CACTGTGGTGGTAGGTAGGGAGAT    300 bp                                      60ºC
  19                                    ACAAAGCCAGGATCAGAACCCAGA     GTCCAGAGTCACCCATGCTCTGCA    323 bp                                      62ºC
  20                                    TGGGTATGAGGGTGCACCAGAGCT     GCATCAGAGGAGTCAATGGAAAAG    330 bp                                      62ºC
  21                                    TAGGCTGTTACCCTTCCTAAGGTA     GCCTCTGACCCTGTGACTGCAGTG    374 bp                                      62ºC
  22                                    GGACCTCAGGTAGGAAGGAGGCAG     TGTGCAGGGAGGTGCAGGGTTGTG    390 bp                                      62ºC
  23                                    TCCTATTTGAGTGATGTGCCTCTC     ATGGTCTGAGAGTCCTGATGAGAC    390 bp                                      62ºC
  24                                    AGATGGCACCAAGCTGGTGACCTT     TCTGGGCACAGATAGACATGGCAT    290 bp                                      62ºC
  25                                    GGCAATCTCACAGTCCCCTAATAA     TTTTTGCCAGGGAGGACCATCTAA    508 bp                                      60ºC
  26                                    ACTCTTTACCTGTATCATTACCAT     GCCTCCATGGACACATAATCAGTT    306 bp                                      60ºC
  27a[\*](#TFN1){ref-type="table-fn"}   AGCCGAGAGCCTTTTAGAGCCG       GTCCCGCCGCATCTTCTGGA        274 bp                                      64ºC
  27b[\*](#TFN1){ref-type="table-fn"}   TCCAGAAGATGCGGCGGGAC         AGGGGAGGTGGGAGGAGGAAGT      266 bp                                      64ºC
  28                                    TCCCACTTCCCTTCCTCTGCCT       CAGCACTCCTCTCTATCCCCACCT    438 bp                                      56ºC
  29                                    GGTGGGGATAGAGAGGAGTGCTGA     TGTGGCAGGGTTTGGGCTGT        315 bp                                      64ºC
  30                                    GAGAAGGGCAAGGGTGGGGT         CCTGAGAGGAGAAGGAGGTGGG      422 bp                                      58ºC
  31                                    TTGTCCCCATCCACACCCTCCA       GCTCCGACTGCGACTCCTCATACT    469 bp                                      56ºC
  32                                    GCTGAAGAGTGAGCCTTGTCCC       TCCGCTGGAACCCAACTGCT        396 bp                                      56ºC
  33                                    AGTATGAGGAGTCGCAGTCGGA       GGGGATGAGAACAGGGAGCCAA      500 bp                                      60ºC
  34                                    CTGCCCTGTGCCCTGACTGT         CCAGCCTCGGTTCCCTTCACT       500 bp                                      64ºC
  35                                    GTGAAGGGAACCGAGGCTGGC        GTTGGGCAGAGCAGGAAAAGCA      364 bp                                      62ºC
  36                                    TCCGTGCCAACGACGACCTGAA       GTCCTCACACACTTGCTGCCCA      497 bp                                      60ºC
  37                                    TGGGCAGCAAGTGTGTGAGGA        GGTTGTCACTGTGGCTATGGTGC     391 bp                                      62ºC
  38 / 39                               ACCTTCTATGACTGTGCCATCTTCAC   GTTTGAGGGTGCTCTGTCTGG       464 bp                                      62ºC
  40                                    ATGCCCTGTCCCTGCCCAATAC       TTTCCACCTCCCCTATGCCAGACC    268 bp                                      60ºC

Necessary more than one primer pair to cover the exon;

Size of the amplified fragment;

Annealing temperature

###### 

Primers for MYBPC3 sequencing

  Exon   Forward Primer 5\'-3\'      Reverse Primer 5\'-3\'      Amplicon[\*](#TFN4){ref-type="table-fn"}   A.T.^[†](#TFN5){ref-type="table-fn"}^
  ------ --------------------------- --------------------------- ------------------------------------------ ---------------------------------------
  2      GACCTCAGCTCTCTGGAATTCATC    GCTCAGAGGCCACGTCCTCGTCAA    311 bp                                     62ºC
  3      GTGCACGCTCCAACCAG           CAGCAAAGGCAAGAAAGTGTG       429 bp                                     65ºC
  4      CTGGGACGGGGAGGAGAATGTG      GCTTTTGAGACCTGCCCTGGAC      385 bp                                     62ºC
  5      GGGCACCTGCGGTCCCAGCTAACT    ACGCGGGCTGAGAAGGTGATG       378 bp                                     62ºC
  6      CTACCCCTGGAGCCCCCGATGACC    TGCCTCCCAGATTCCCCACACC      449 bp                                     62ºC
  7      CTGGAGCTCCTGGTCTTATGTGAT    GGAGCCGTGACACCAAGATGATAA    528 bp                                     62ºC
  8      GCTTCTCAAACGGCCCCCTCTG      AGCTCCGCCCCGCAAATCATCC      213 bp                                     62ºC
  9      GGGCTGGGGATGATTTG           GGAGGGAGAAAGGGACACTA        226 bp                                     63ºC
  10     AATCTGGCTAGTGTCCCTTTCTCC    AGCCCTTTAACTCCTTCCACACTG    322 bp                                     62ºC
  11     TCGGCCCAACTGACTTA           CCCATGGGCCTTTACTT           389 bp                                     58ºC
  12     CGGCTCCCCACGGACAG           CCCAGGCCAGGCAGGACT          405 bp                                     67ºC
  13     TCCCCAGCCCCTCTTCA           GCCGGACTCCGCTCTTT           515 bp                                     62ºC
  14     GGCGGCACAGAGGGGATTG         ACCGGCAGGAGCAAAAGGATG       402 bp                                     62ºC
  15     ATCCGGCTGACCGTGGAACT        CAGTGCGCCCCGTGATAATC        375 bp                                     65ºC
  16     AACACTTCAACGGCCCCTTCTG      GCCCCCTCCTCCGATACTTCACAC    451 bp                                     62ºC
  17     CGGACGACGCAGCCTACCAGT       GTCAGCTCCACCCCGTCCTTCA      366 bp                                     62ºC
  18     GGAGGAGGGGGCGCAAGTCAAAT     GTCAAAGGCCCAAGGTCACAGAGG    400 bp                                     62ºC
  19     ACAGGCACACGTGTTTTCAC        CAGTCTCCACCTGTCCCATC        345 bp                                     61ºC
  20     AGAATACCAACAAGCCAGGACAAG    GCGGGAAAGTGAGCAGAACC        402 bp                                     62ºC
  21     TGCCTTTGCCCCCGTGCTACTTG     GCCCCAGGACCCCCACTTTTGAT     187 bp                                     62ºC
  22     TCCTCCTGGCTCTCCCGTTTCTCT    GCGCCCCTCTGCTGCTTCTTC       379 bp                                     62ºC
  23     GCTCCTCTGCTCCCTACTTCC       ATGGCCATCAGCACACTTCAC       310 bp                                     62ºC
  24     TCGGTGCCACAGAGATGATTTTGA    GGCTGCCCCTCTGTGTTCTCCA      367 bp                                     62ºC
  25     CCTGTGGCGGTTAGTTGG          CACCGGTAGCTCTTCTTCTTCTTG    350 bp                                     62ºC
  26     CCGAGGGAAGGTGGTGTGG         TCTGTAAAATGCGGCTGAGTATCC    404 bp                                     62ºC
  27     GGAAGTGCCCCCTATGT           TCGCACTGCTCAAAGAAG          457 bp                                     62ºC
  28     TCAGAGGAGTGGGCAGTGGGAGTG    CTGGGGTGTCAATGGCGGGTCTT     292 bp                                     62ºC
  29     GCCTGGAGTTGCTGTGTTAG        GGCTGCCCCTCTTTGGTC          467 bp                                     62ºC
  30     GCGGCCGGCCCTTGGAGT          TGGAAAATGTGAGCTGTGGGTTGG    356 bp                                     62ºC
  31     GCATTCAGGCACTTACCAGGTGACG   CACGGTGAGGACAGTGAAGGGTAGC   527 bp                                     60ºC
  32     GGCCGCAGCTACCCTTCAC         GGCCCCTCTCCCTGTTCC          392 bp                                     65ºC
  33     GGCCTCTCGGTACCAAGTCCTGTC    CAACGTCGGGGCCTGTGAGC        232 bp                                     65ºC
  34     GCAGGGCCATGGTACTCACTCTTG    CCGCCCGCTCTTCCCATCTC        404 bp                                     62ºC
  35     CACAGTGACATGGCCTCCTCTTCT    GCCCCTACAGCCTCCCATTTACT     159 bp                                     62ºC

Size of the amplified fragment;

Annealing temperature.

###### 

Primers for TNNT2 sequencing

  Exon    Forward Primer 5\'-3\'        Reverse Primer 5\'-3\'      Amplicon[\*](#TFN6){ref-type="table-fn"}   A.T.^[†](#TFN7){ref-type="table-fn"}^
  ------- ----------------------------- --------------------------- ------------------------------------------ ---------------------------------------
  2       ACAGCTCATGAGGGGTGGAACTA       GTGCTCTGCCTGGGATCTACAACC    376 bp                                     65ºC
  3 / 4   ATGAGAACGGCAGGCCAGGCTAGTG     GTTTGCCTCAAGACCCGAGCAACC    506 bp                                     65ºC
  5       GTGGCGGGAGGTAGCCGACAGT        TGGGCAATCAATGGTTGAATCTTA    403 bp                                     65º C
  6       TTGACCCAGCGCTTCTCTTGTGTC      ACTGGGTGCCACCAATGCAACTTC    449 bp                                     65º C
  7       CCAGTGCCGGGAGGGACTCAC         CAGCCCGTGTCCACTGCACCATAC    262 bp                                     65º C
  8       GGATCAGGGGCCCTGCCTGTCCTGACA   TCCTCCTCCTCTTTCTTCCTGTTCT   538 bp                                     62º C
  9       GCCAGGCCCTGCCAGAGGTCTT        CCCTGGGGGAGGCCTGAAACAG      494 bp                                     70º C
  10      ACGTCCGTGGAGCTGGTTGAAAGT      CCCGGCCAATATTGTCTCTTGACT    373 bp                                     62º C
  11      TGGGAGCTACCCTCTCAGAA          CACAGCAGCTGGGAATCTCT        369 bp                                     60º C
  12      GTAAACCCGGCTGACTACAG          AGCCAGCCCAATCTCTTCAC        258 bp                                     62º C
  13      CAGGGGGTTTGGGGAGGGTTAG        GTGGGGCACCTGCTCAGTTCTCT     402 bp                                     60º C
  14      GGAGGGCCCTTTCTTACTGGAC        CCGGACCCAGTGAACCAGGAGGAG    207 bp                                     68º C
  15      GCCCCTCCTGACCCTTAACTATCC      CGGAGGAGCCAGAGAAGGAAACCT    353 bp                                     62º C
  16      GGGGGTGAAATGTGGGGCGGAGAA      GTGTGGGGGCAGGCAGGAGTGGTG    383 bp                                     62º C

Size of the amplified fragment;

Annealing temperature.

Variant pathogenicity prediction
--------------------------------

Effects of missense mutations were predicted by using the PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>), SIFT/PROVEAN (<http://SIFT.jcvi.org/>) and PredictProtein (<http://predictprotein.org/home>) tools. A5YM48 and Q14896 were used as *MYBPC3* reference sequences (UniProtKB).

Results
=======

A seventeen-year-old (y) male proband presenting with a clinical manifestation of HCM and syncope history was submitted to a cardioverter-defibrillator implantation for syncope primary prevention. The diagnosis was based on TTE and showed a reverse curve asymmetric septal hypertrophy, with 39-mm thickness with preserved LV systolic function and normal LV ejection fraction ([Figure 1](#f1){ref-type="fig"}). Additionally, diastolic type II dysfunction, maximum gradient LV/Aorta of 25 mmHg, systolic anterior motion of the mitral valve, obstruction of the LV outflow tract, and enlarged left atrium (46 mm) were also present. The ECG showed LV and LA overload and 24-hour Holter monitoring failed to document the presence of ventricular tachycardia. The risk of SCD was considered high, at 7.69%. The genetic analysis identified a compound heterozygous missense variant, c.1624G\>C (p.E542Q) and c.1828G\>C (p.D610H) in *MYBPC3* ([Figure 2](#f2){ref-type="fig"}). The variant p.E542Q (rs121909374) has been associated with HCM in ClinVar and in the Human Gene Mutation Database (HGMD). The *in silico* analysis performed by PolyPhen-2 predicts this variant as possibly harmful, while SIFT/PROVEAN and PredictProtein classify this mutation as tolerable. On the other hand, p.D610H (rs371564200) is classified as a variant of uncertain significance (VUS), although pathogenicity prediction tools rank p.D610H as probably deleterious/harmful. Both variants affect conserved residues in the polypeptide chain ([Figure 2](#f2){ref-type="fig"}).

Figure 1TTE of the proband and CMR of the family. A) TTE image of the four heart chambers and aorta revealing the reverse curve septal hypertrophy. B) Parasternal short-axis view showing the septal hypertrophy. C) Parasternal long-axis view displaying the LV and septal hypertrophy and the enlarged left atrium. The white arrow shows the systolic anterior motion of the mitral valve. D) TTE image showing the obstruction and the turbulence in the outflow tract of the left ventricle (white arrow). Mild mitral regurgitation in the left atrium is visible. CMR of the proband\'s father (E), aunt (F) and mother (G), showing no hypertrophy or fibrosis signs. CMR in the inversion-recovery sequence (delayed enhancement) in 4CH axes (E1, F1, G1), LVSV (E2, F2, G2) and 2CH (E3, F3, G3). RA: right atrium; RV: right ventricle; LA: left atrium; LV: left ventricle; Ao: aorta.

Figure 2A) Pedigree showing five generations of the maternal family. The proband is the only HCM-affected member. The family variant allele carriers are indicated by E542Q+ and D610H+. B) Electropherograms of the compound missense variant regions of the MYBPC3 gene of the proband. C) Multiple species alignment of the myosin-binding protein C amino acid sequence for residues 538 to 546 and 606 to 614. The conserved residues, glutamic acid and aspartic acid, are indicated by a rectangle.

The proband is the only member that manifests the HCM phenotype in his family. His father was adopted, so only maternal ascendants are known. The constructed heredogram revealed 30 relatives, over five generations, in which only one unexplained death of a 30-year-old female with no HCM diagnosis was detected ([Figure 2](#f2){ref-type="fig"}).^[@r14]^

Genotyping of maternal family members - grandmother (59y), aunt (29y), uncle (35y) and mother (39y) - detected the p.D610H variant. All family members were asymptomatic, with normal TTE and ECG, with no evidence of VH. On the other hand, the allele p.E542Q was detected in the father (40y) and a paternal sibling (8y), both with normal clinical assessment results ([Table 4](#t4){ref-type="table"}). CMR was performed in the mother, aunt, and father, and resulted in normal findings, specifically normal LV wall thickness and no signs of fibrosis ([Figure 1](#f1){ref-type="fig"}).

###### 

Clinical assessment data of the individuals

  ----------------------------------------------------------------------------------------------------------------------------
  Epidemiology   ECG   TTE                                                                                                
  -------------- ----- ----- ----- -------- ----- ----- ----- ----- -------- --------------- ---- ---- ---- -------- ---- ----
  III.8          59    F     No    D610H    No    No    No    No    \-       \-              10   No   No   No       No   28

  IV.2           40    M     No    E542Q    No    No    No    No    \-       \-              9    No   No   No       No   35

  IV.3           39    F     No    D610H    No    No    No    No    \-       \-              9    No   No   No       No   37

  IV.6           29    F     No    D610H    No    No    No    No    \-       \-              8    No   No   No       No   32

  IV.7           35    M     No    D610H    No    No    No    No    \-       \-              8    No   No   No       No   36

  V.1            8     M     No    E542Q    No    No    No    No    \-       \-              7    No   No   No       No   37

  V.2            17    M     Yes   D610H\   Yes   Yes   Yes   Yes   Septal   Reverse Curve   39   25   No   Type I   No   46
                                   E542Q                                                                                  
  ----------------------------------------------------------------------------------------------------------------------------

The identification numbering (ID) of individuals follows the standard adopted in the pedigree charts ([Figure 2](#f2){ref-type="fig"}); ECG: electrocardiography; TTE: Transthoracic echocardiography; (Y): years; HCM: hypertrophic cardiomyopathy; LAO: left atrial overload; LVO: left ventricular overload; ABN T wave: abnormal T wave; LVH + : left ventricular hypertrophy showed by echo; LVH type: type of the left ventricular hypertrophy; Max LVWT: maximal thickness of the left ventricular wall; LVOG: left ventricular outflow gradient; LVSD: left ventricular systolic dysfunction; LVDD: left ventricular diastolic dysfunction; SAM: systolic anterior motion; LA size: left atrial size.

Discussion
==========

The present study reports on a young individual with severe HCM who carries a compound *trans*-heterozygous variant in the *MYBPC3* gene, with one allele - p.D610H - inherited from the mother and the other - p.E542Q - inherited from the father.

Individuals with a single variant did not show any HCM phenotype. The p.E542Q variant, found in the paternal relatives, is associated to HCM, with good prognosis and moderate wall hypertrophy, although only a few studies mentioning this mutation are available^[@r10],[@r15]-[@r17]^. Pathogenicity prediction of p.E542Q is in agreement with literature data^[@r18]-[@r21]^.

Moreover, the p.D610H variant, identified in the maternal relatives, also did not manifest any HCM phenotype, even in the oldest investigated familiar member (59y). The association between p.D610H and HCM remains uncertain, despite the fact that pathogenicity predicting tools classified this as probably pathogenic. Only a single study in the literature has identified this mutation, although it did not correlate it with the disease^[@r22]^.

In general, a single HCM-heterozygous mutation is sufficient to affect myocardial function and lead to hypertrophy; however, early studies have associated variants in the *MYBPC3* gene with incomplete penetrance, mild VH, low SCD risk and benign clinical evolution^[@r23]-[@r25]^.

In conclusion, it is suggested that, individually, the p.E542Q and p.D610H variants generate mild changes in protein structure/function, insufficient to cause a strong phenotype. However, the expression of these variants in *trans* may be responsible for early disease onset, a more severe clinical phenotype and increased risk of malignant events in the proband. In other words, double or compound variants by themselves are not decisive for a poorer HCM prognosis, but the allelic composition of these variants may be determinant in this regard.

Study limitations
-----------------

The present study investigated the three major HCM-genes that account for approximately 60-70% of HCM cases^[@r5],[@r14]^. However, several other genes have already been associated to this disease^[@r5],[@r14]^, which are yet to be investigated.
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